42 results about "Attenuated Bacteria" patented technology

The present application generally discloses delivery of an agent which can be therapeutic or prophylactic and, more particularly, the preparation and use of attenuated bacteria, such as Salmonella, containing a bacteriophage in which the genome of the bacteriophage has been modified to encode for a gene product of interest, e.g., an antigen or an anti-tumor protein. The bacteria functions as a vector for delivering the bacteriophage encoded gene product of interest to an appropriate site of action, e.g., the site of a solid tumor.

The present application discloses the preparation and use of attenuated tumor-targeted bacteria vectors for the delivery of one or more primary effector molecule(s) to the site of a solid tumor. The primary effector molecule(s) of the invention is used in the methods of the invention to treat a solid tumor cancer such as a carcinoma, melanoma, lymphoma, or sarcoma. The invention relates to the surprising discovery that effector molecules, which may be toxic when administered systemically to a host, can be delivered locally to tumors by attenuated tumor-targeted bacteria with reduced toxicity to the host. The application also discloses to the delivery of one or more optional effector molecule(s) (termed secondary effector molecules) which may be delivered by the attenuated tumor-targeted bacteria in conjunction with the primary effector molecule(s).

Provided are reagents and methods for administering an attenuated bacterium and a binding compound for treating a cancerous or infectious condition, where the binding compound comprises an antibody or an antigen binding site derived from an antibody.

The invention provides strains of bacteria, especially enterotoxigenic E. coli, attenuated by mutations in the genes encoding enterotoxins (LT, ST, EAST1) and optionally further attenuated by deletion of additional chromosomal genes. In addition the invention provides strains of attenuated bacteria expressing immunogenic but non-toxic variants of one or more of these enterotoxins. These bacteria are useful as a vaccine against diarrhoeal disease.

The present invention relates to the use of live attenuated bacteria for the manufacture of a vaccine for submucosal administration.

The present invention relates to a polypeptide based toxin that originates from Clostridium perfringens. The invention further relates to immunogenic compositions comprising the toxin and methods to vaccinate animals, for example chickens, such that they are less susceptible to clostridial diseases. Methods to determine whether an animal has been exposed to the toxin, polynucleotides encoding the toxin and attenuated bacteria that express a reduced or less active form of the toxin are also disclosed.

The present invention relates to recombinant virulence attenuated Gram-negative bacterial strains and its use in a method of treating cancer in a subject.

A method for replacing a target nucleotide / polynucleotide sequence of a bacterial chromosome with a different nucleotide / polynucleotide sequence, which method comprises: (a) providing a bacterium which is capable of expressing: (1) the gamma genes exo or a functional equivalent thereof and bet or a functional equivalent thereof, but not the gamma gene gam or a functional equivalent thereof; or (2) the gamma gene bet or a functional equivalent thereof and gam or a functional equivalent thereof; (b) providing a polynucleotide construct which comprises: (i) a sequence which corresponds to a first sequence flanking the left hand side of the target sequence; (ii) a second sequence corresponding to a sequence flanking the right hand side of the target sequence; and (iii) positioned between (i) and (ii), the donor sequence; and (c) introducing the polynucleotide construct into the bacterium, thereby to replace the target nucleotide sequence with the sequence different from that of the target nucleotide sequences. The method can be used in the preparation of attenuated bacteria and in the identification of essential genes.

The present invention relates to a bacterium attenuated by a mutation in at least one ABC transporter gene wherein the mutation renders the corresponding ABC transporter protein non-functional and wherein the attenuated bacterium persists in a subject.

The present invention relates to live attenuated bacteria of the species Pasteurella multocida, to live attenuated vaccines comprising such live attenuated bacteria, to the use of such bacteria for the manufacture of such vaccines, to methods for the preparation of such vaccines and to diagnostic tests for the detection of such bacteria.

The invention discloses AHFGDS (aeromonas hydrophila five-gene deletion strain) attenuated bacteria without antibiotic markers and an application. Based on high-virulent strain ZYAH72, five virulence factors including aerA, alt, ahp, ast and hly are deleted with a genetic engineering method and a marker-free screening strategy, an AHFGDS with five genes deleted is obtained, and the preservation number of the strain is CCTCC (China Center for Type Culture Collection) No:M2015798. Compared with wild bacteria, the strain can still be subjected to a strong reaction with positive serum even if the pathogenicity is remarkably weakened. Experiments prove that the strain serving as an attenuated live vaccine can effectively protect susceptible aquatic animals against infection of wild AHFGDSs.

Methods, pharmaceutical compositions and vaccines comprising an attenuated bacteria that expresses a recall antigen are disclosed for treatment of cancer.

The present invention relates to recombinant virulence attenuated Gram-negative bacterial strains for use in a method of treating a malignant solid tumor in a subject.

The invention discloses an attenuated bacteria vector tuberculosis vaccine carrying tuberculosis genes as well as a preparation method and application thereof. The preparation process includes the following steps: firstly, structuring a eukaryotic expression plasmid containing mycobacterium tuberculosis Ag85B and ESAT-6Agb5B genes; and secondly, using the electroporation method to convert the structure eukaryotic expression plasmid into attenuated Salmonella typhimurium which can stably express mycobacterium tuberculosis proteins. The combined utilization of Salmonella typhimurium SL7207 (pVAX-1-ESAT6-Ag85B) and BCG can achieve greater immune protective effect in resisting mycobacterium tuberculosis infection than by the BCG only; and the SIgA level of mucosa and serum produced by the Salmonella typhimurium SL7207 (pVAX-1-ESAT6-Ag85B) and BCG combined is higher than BCG and DNA vaccines. In addition, the Salmonella typhimurium SL7207 (pVAX-1-ESAT6-Ag85B) has greater immune protective ability than DNA vaccines or Salmonella typhimurium SL7207 (pVAX-1-Ag85B). The invention has the advantages of simple method, low cost, and convenient use, and can not only resist Salmonella typhosa infection, but also achieve immune protection against mycobacterium tuberculosis infection. Moreover, the stable expression of the mycobacterium tuberculosis proteins after being immunized can induce mucosal and systematic immune responses, and the invention has remarkable economic benefits.

The present invention relates to live attenuated RTX-toxin producing bacteria of the family Pasteurellaceae, of which the attenuation is due to the fact that they produce RTX toxin in a non-activated form. The invention also relates to vaccines for the protection of mammals against infection with RTX-toxin producing bacteria of the family Pasteurellaceae, and to methods for the preparation of said live attenuated bacteria and vaccines.

The present invention relates a combination for use in the treatment and / or prevention of mastitis containing i) an agonistic anti-CD40 monoclonal antibody or a CD40 ligand or a vector coding for the anti-CD40 antibody or a vector coding for the CD40L; and ii) inactivated or attenuated bacteria selected from the group consisting of Staphylococcus, Streptococcus, Listeria or Escherichia.

The invention relates to an non-pathogenic and / or attenuated bacterium which is capable of inducing apoptosis in macrophages.

A host is immunized against infection by a strain of Chlamydia by initial administration of an attenuated bacteria harbouring a nucleic acid encoding a Chlamydia protein followed by administration of a Chlamydia protein in ISCOMs. This procedure enables a high level of protection to be achieved.